StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc. (CAI) company profile

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.94−1.06 (-5.05%)

Close on Nov 17, 2026Market cap $5.63BP/E –Yield –

About Caris Life Sciences

Services-Medical Laboratories, SIC 8071

Caris is a precision medicine and biotechnology enterprise that develops and commercializes artificial intelligence-powered molecular profiling solutions focused primarily on oncology. Its offerings span the cancer care continuum, including early detection, minimal residual disease tracking, therapy selection, and treatment monitoring, as well as drug target discovery. The core product lines include the MI Profile platform for tissue-based whole exome and whole transcriptome sequencing, the Caris Assure platform for blood-based profiling, and the Precision Whole Genome platform. Caris serves clinical, academic, and biopharmaceutical markets, delivering molecular reports to treating oncologists while collaborating with biopharma companies and academic centers on biomarker research and therapeutic pipelines.

The company provides profiling services across major health systems, academic cancer institutions, and community settings, serving more than 6,000 ordering physicians in the United States. Its clinical solutions are available across U.S. states and Puerto Rico, and internationally via distributors and direct hospital contracts. In addition, Caris coordinates research with cancer centers worldwide through the Caris Precision Oncology Alliance. The provided text does not state the company's headquarters location or official website.

Summary of the business section of Caris Life Sciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Caris Life Sciences, Inc.
Founded
2008
Headquarters
Irving, TX
Address
750 W John Carpenter Freeway, Suite 800 75039
Phone
(866) 771-8946
Employees
1,846, Dec 31, 2025
Industry
Services-Medical Laboratories
Incorporated in
Texas
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Dallas, Texas

Stock & identifiers

Ticker
CAI
Exchange
Nasdaq
IPO date
Jun 20, 2025
Shares outstanding
283M, Aug 3, 2026
Public float
$3.87B, Jun 30, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
2019410
CUSIP
142152107
ISIN
US1421521071
FIGI
BBG00255V2N4
Share class FIGI
BBG00255V2P2
LEI
549300LX5LO78M5VPY43
EIN
85-2077369

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Brian J. BrilleSee Remarks, Director1,130,303
David D. HalbertSee Remarks, Director123,599,535
John Russel DentonSee Remarks184,039
David Baxley SpetzlerPresident1,302,083
Luke Thomas PowerSee Remarks153,771
Laura I. JohansenDirector343,897
T. Danny PhillipsDirector133,060
David Paul FredricksonDirector31,813
Peter M. CastlemanDirector10,683,714
Jeff L. VacircaDirector62,863
Jon HalbertDirector1,490,406
Lloyd MinorDirector31,813
Joseph E. GilliamDirector29,321
Jonathan Kenneth Charles KnowlesDirector308,979
George PosteDirector529,431
Caris Halbert, L.P.Director123,462,091

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
David Dean Halbert
Chief Executive Officer
$764.92K$3.26M$15.40M–$925.77K$20.35M+804%
David Spetzler
President
$611.93K$703.73K$2.78M$7.47M$14.00K$11.58M+854%
J. Russel Denton
Senior Vice President, General Counsel and Secretary
$458.95K$263.90K$2.09M$2.53M$14.00K$5.35M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 20, 2025
Offer price
$21.00
Securities offered
23,529,412
Gross proceeds
$494.12M
Exchange
Nasdaq
First trading day
Jun 18, 2025
First-day close
$28.00+33.3%
Lock-up ends (est.)
Dec 15, 2025

“than 5% of our outstanding capital stock, and their respective affiliates will collectively beneficially own approximately 66.2% of our outstanding shares of common stock, in each case, based on the initial public offering price of $21.00 per share and assuming no exercise by the underwriters of their option to purchase additional shares of our common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?